UNC Lineberger Comprehensive Cancer Center researchers have identified a possible new drug target for a potentially deadly form of skin cancer that, when blocked in a pre-clinical study in mice, reduced the cancer’s growth.
MRV Research
FDA Grants Priority Review to Frontline Nivolumab in Melanoma
The FDA has assigned a priority review designation to the PD-1 inhibitor nivolumab (Opdivo) as a treatment for previously untreated patients with unresectable or metastatic melanoma. Under the expedited process, the action date for the FDA’s decision is August 27, 2015.
FDA panel backs Amgen’s T-Vec for melanoma
An FDA advisory committee has voted in favour of approving Amgen’s virus-like melanoma therapy, despite questions about its impact on survival.
Uncovering new functions of a gene implicated in cancer growth opens new therapeutic possibilities
Weill Cornell Medical College researchers have shown for the first time that a gene previously implicated in blood vessel formation during embryonic development and tumor growth also induces immune suppression during tumor development. This finding, published April 29 in Nature Communications, opens the door for new therapeutic approaches and vaccine development in treating patients with melanoma and other advanced-staged cancers.